Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 4

1(33.3%)

Phase 2

1(33.3%)

3Total

N/A(1)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT02013479Not ApplicableCompleted

Selenium Supplementation in Autoimmune Thyroiditis

Role: lead

NCT02005250Completed

Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism

Role: lead

NCT00275171Phase 2Completed

rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Role: lead

NCT00150124Phase 4Completed

Block-replacement Therapy During Radioiodine Therapy

Role: lead

All 4 trials loaded